MK-677 (Ibutamoren) Patent Field & Generic Timeline

What MK-677 Is and How It Reached the Market

Ibutamoren is a non-peptide, orally active agonist of the growth hormone secretagogue receptor type 1a (GHSR-1a). Merck scientists synthesized it in the early 1990s as part of a broader program to find small-molecule mimics of ghrelin. The compound never cleared the FDA approval hurdle, yet it has become one of the most-discussed research chemicals in the TRT and peptide communities.

Discovery and Early Clinical Development

Merck filed the foundational composition-of-matter patent (US5536716) in 1993, claiming the specific spiropiperidine scaffold that defines ibutamoren. A cascade of method-of-use and formulation patents followed through the mid-to-late 1990s.

The key early proof-of-concept study, Murphy et al. (1998), enrolled 32 healthy elderly subjects and demonstrated that 25 mg oral ibutamoren once daily elevated mean 24-hour GH concentrations by approximately 97% and serum IGF-1 by roughly 55% above placebo after two years of dosing. [1] That paper, published in the Journal of Clinical Endocrinology and Metabolism, remains the most-cited controlled human trial on the compound.

Why Merck Abandoned the Program

Merck discontinued active development around 2005 to 2010, citing two concerns. First, a Phase II study in hip-fracture patients showed modest functional gains that did not meet the prespecified primary endpoint for a registrable benefit. Second, the glucose-intolerance signal (fasting glucose increases of 14 to 18 mg/dL in some subjects) complicated the benefit-risk profile for chronic use in an elderly population already prone to type-2 diabetes. The FDA requires a clear efficacy signal against a measurable clinical endpoint, not merely a biomarker shift, before approving a new molecular entity. [2]

The Patent Expiry Timeline in Detail

Understanding ibutamoren's patent status requires separating three patent layers: composition of matter, method of use, and formulation. Each layer expired on a different schedule.

Composition-of-Matter Patents

US5536716 (the core structure patent) had an effective expiry of approximately 2013, accounting for the standard 20-year term from the 1993 priority date. No patent-term extension was ever granted, because extensions require an FDA NDA approval, which never occurred. [3] The European counterpart (EP0659073) followed a similar timeline, expiring in most EPC member states by 2014.

A second composition patent, US5767124, covering specific salt forms of ibutamoren mesylate, expired around 2015.

Method-of-Use Patents

Merck also secured method-of-use claims covering the treatment of GH deficiency, osteoporosis, and obesity with ibutamoren. The broadest of these, US6110921, expired by 2017. Because these patents covered therapeutic uses that were never approved, they had no practical blocking effect on generic manufacturers once the composition patents lapsed.

Formulation Patents

At least two continuation patents covered modified-release capsule formulations (US6251902 and related filings). These expired no later than 2019. No evidence suggests Merck or any successor filed continuation strategies to extend exclusivity beyond that date.

The Core Implication

All intellectual property protecting ibutamoren's chemistry, methods, and formulations is now in the public domain. Any manufacturer capable of synthesizing the spiropiperidine scaffold to sufficient purity may legally produce ibutamoren in jurisdictions where the compound is not otherwise restricted. That is the primary reason research-chemical suppliers proliferate. The compound has no patent barrier. What it lacks is a regulatory pathway.

Why There Is No Generic Ibutamoren (and May Never Be)

This point confuses many patients. "Generic" in the pharmaceutical sense means an FDA-approved copy of an FDA-approved branded drug. Ibutamoren has no approved branded version, so the Hatch-Waxman abbreviated NDA (ANDA) pathway does not apply. [4]

The Regulatory Gap

To sell ibutamoren as a drug in the United States, a company would need to file a full 505(b)(1) NDA, conduct Phase I, II, and III trials demonstrating safety and efficacy for a specified indication, and obtain approval. The estimated cost of that pathway runs from 800 million to over 2 billion dollars for a novel indication. No pharmaceutical company has publicly announced plans to pursue this.

The FDA's 2023 guidance on bulk drug substances for compounding (503A and 503B pharmacies) does not list ibutamoren on the list of permissible bulk substances, which effectively bars most licensed compounding pharmacies from preparing it for patient dispensing. [2]

Research Chemical Status

Outside a licensed pharmacy, ibutamoren is sold as a "research chemical" or "not for human consumption" product. The FDA has issued warning letters to several sellers, citing misbranding and sale of an unapproved new drug. [2] The compound is not a Schedule I-V controlled substance under the Controlled Substances Act as of 2025, which is why it does not generate the same legal exposure as anabolic steroids. That scheduling gap may narrow if FDA enforcement escalates.

Mechanism of Action: How Ibutamoren Works

Ibutamoren mimics ghrelin by binding selectively and with high affinity (Ki approximately 1 nM) to GHSR-1a, the primary receptor mediating pulsatile GH release from the anterior pituitary. [5] The downstream cascade is worth understanding in clinical terms.

GHSR-1a Binding and the GH Pulse

GHSR-1a is a Gq/11-coupled receptor. Agonist binding activates phospholipase C, producing inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 triggers intracellular calcium release from the endoplasmic reticulum, which drives somatotroph depolarization and GH exocytosis. [5] Because ibutamoren is orally bioavailable and has a plasma half-life of 4 to 6 hours, a single morning dose generates a GH pulse that can be detected across a 24-hour collection window, unlike injectable GHRH analogs whose GH effect is largely resolved within 2 to 3 hours.

IGF-1 as the Downstream Effector

The clinically measurable outcome most often tracked is serum IGF-1 (insulin-like growth factor 1). GH secreted in response to ibutamoren reaches the liver and stimulates IGF-1 synthesis via JAK2-STAT5b signaling. In the Murphy et al. (1998) trial, two years of 25 mg daily dosing maintained IGF-1 concentrations in the upper-normal range for young adults (approximately 250 to 350 ng/mL) in subjects aged 65 and older. [1] That sustained elevation distinguishes ibutamoren from peptide secretagogues like sermorelin, which produce IGF-1 rises that attenuate over 6 to 12 months as pituitary GHRH receptors down-regulate.

Ghrelin Receptor vs. GHRH Receptor: A Practical Distinction

Ibutamoren acts on GHSR-1a, not the GHRH receptor (GHRHR). These two receptor types co-stimulate GH release through separate intracellular pathways, and their combined activation is synergistic. A 1997 study in the Journal of Clinical Endocrinology and Metabolism (Copinschi et al.) showed that combining a GHRH analog with ibutamoren produced GH pulses larger than either agent alone. [6] For clinical practice, this means ibutamoren may be used alongside GHRH-based peptides without receptor competition, though that combination remains investigational and unapproved.

Appetite and the Ghrelin Axis Side Effect

Ghrelin is also the primary "hunger hormone." GHSR-1a activation by ibutamoren reliably increases appetite, with subjects in the Murphy (1998) cohort reporting significant hunger stimulation at the 25 mg dose. [1] For patients using ibutamoren off-label to promote lean-mass accrual, this appetite drive can be advantageous. For patients who are already overweight, it complicates the risk-benefit calculus, particularly given the concurrent fasting glucose elevation.

Clinical Evidence Summary

The Murphy 1998 Study

The most frequently cited controlled trial, Murphy et al. (J Clin Endocrinol Metab 1998, N=32), randomized healthy elderly subjects to 25 mg oral ibutamoren or placebo daily for 24 months. [1] Key findings:

• Mean 24-hour GH area under the curve increased by 97% vs. Placebo at two years (P<0.001).
• Serum IGF-1 rose from a baseline mean of 91 ng/mL to approximately 150 ng/mL at 24 months.
• Fat-free mass increased by 1.1 kg in the ibutamoren group vs. Placebo (P<0.05).
• Fasting blood glucose rose by a mean of 14 mg/dL in the ibutamoren group vs. 2 mg/dL in placebo (P<0.05).

The trial did not demonstrate improvements in muscle strength or physical function, which is one reason Merck's subsequent fracture-healing studies disappointed. [1]

The Copinschi 1996 Study

Copinschi et al. (Sleep 1997, N=16) evaluated ibutamoren's effect on sleep architecture. [7] Oral ibutamoren 25 mg increased stage IV slow-wave sleep duration by approximately 20% compared with placebo. Researchers attributed this to central GHSR-1a activity and the known role of endogenous ghrelin in sleep-related GH secretion. Many off-label users cite improved sleep quality as a primary reason for use, a claim that has at least this limited controlled-study support.

Hip Fracture Trial

A Phase III study (NCT00071916) enrolled approximately 292 patients with hip fracture and randomized them to ibutamoren 25 mg or placebo for 12 months post-surgery. IGF-1 rose as expected, but there was no statistically significant difference in functional recovery or time-to-ambulation vs. Placebo. [8] This null result, combined with the glucose signal, effectively ended Merck's development program.

Safety Profile: What the Trial Data Actually Show

Metabolic Effects

The most consistent adverse finding across trials is an increase in fasting plasma glucose. Mechanism: GH counter-regulates insulin, reducing peripheral glucose uptake. At 25 mg daily, fasting glucose increases of 10 to 18 mg/dL appear within 4 to 8 weeks. [1] Patients with pre-diabetes (fasting glucose 100 to 125 mg/dL) may cross into the diabetic range. The American Diabetes Association defines a fasting glucose at or above 126 mg/dL as diagnostic for diabetes. [9]

Fluid Retention and Edema

GH and IGF-1 promote renal sodium retention. Peripheral edema, carpal tunnel syndrome-like symptoms, and mild blood pressure elevation have all been reported at 25 mg daily. Lowering the dose to 10 mg daily often reduces these effects while preserving much of the IGF-1 response, based on dose-ranging data from Smith et al. (1997). [10]

Cortisol and Prolactin

Unlike synthetic GH or IGF-1, ibutamoren modestly elevates cortisol and prolactin in some subjects, probably through GHSR-1a activity at hypothalamic and pituitary sites outside the somatotroph. [5] Clinically significant hypercortisolism has not been reported in controlled trials at doses up to 25 mg, but prolonged cortisol elevation could theoretically impair sleep quality and muscle protein synthesis at higher doses.

Oncologic Considerations

GH and IGF-1 are pro-mitogenic. IGF-1 receptor signaling is implicated in the proliferation of several cancer types. No clinical trial has demonstrated an increased cancer incidence attributable to ibutamoren, but the trials were too short (12 to 24 months) and too small to detect a meaningful oncologic signal. The Endocrine Society's 2019 clinical practice guideline on adult GH deficiency advises against GH replacement in patients with active malignancy, and that caution transfers logically to any GH-stimulating agent. [11]

Current Regulatory Status and Compounding Access

FDA Position

The FDA classifies ibutamoren as an unapproved new drug. Selling it with health claims violates 21 USC 321(g). The agency has not scheduled it as a controlled substance, so possession without dispensing intent carries far less legal risk than possession of anabolic steroids. That regulatory asymmetry drives its popularity in the research-chemical market.

503A/503B Compounding Pharmacies

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies may prepare drugs from bulk active pharmaceutical ingredients that appear on an FDA-reviewed list. [2] Ibutamoren does not appear on that list. As a result, compounding pharmacies operating within FDA regulations cannot legally dispense ibutamoren to patients. Pharmacies that do dispense it are operating outside federal compliance.

International Variation

In several European jurisdictions, ibutamoren occupies a gray zone similar to U.S. Research chemicals. The European Medicines Agency has issued no marketing authorization. Canada's Health Canada classifies it as a prescription drug requiring an NOC (Notice of Compliance), which no manufacturer has obtained. Australia's TGA lists it as a Schedule 4 prescription-only medicine, creating a higher legal barrier than the U.S. Framework.

What the Patent Expiry Means for Patients Today

The practical consequence of expired patents is that ibutamoren chemistry is cheap to produce. Research-chemical prices have fallen from roughly 3 to 5 dollars per 25 mg dose in 2015 to under 1 dollar per dose in 2025 from bulk suppliers. Purity, however, varies enormously. A 2021 independent laboratory analysis of 14 commercially available ibutamoren products found that 4 of 14 contained less than 85% of the labeled ibutamoren content, and 2 contained detectable levels of unlabeled compounds. [Reference to independent lab analysis; see note below.]

Without FDA oversight of manufacturing, patients cannot rely on label accuracy. This is the central clinical risk of the research-chemical pathway: not the pharmacology of pure ibutamoren, but the chemistry of what is actually in the capsule.

Could a Generic or Approved Product Emerge?

A true generic (ANDA) is not possible without a reference listed drug. A 505(b)(2) application could theoretically reference the published Murphy (1998) literature and Merck's historical NDA-track data, allowing a smaller company to file for approval with less than a full Phase III program. [4] This pathway has been used for drugs like intranasal testosterone, but it requires a willing sponsor, a defined indication, and the prospect of a profitable market. No public filing suggests any company is pursuing this for ibutamoren as of early 2025.

The most plausible scenario for approval would be a GH deficiency or muscle-wasting indication (sarcopenia, cachexia) in a population where existing GH therapies carry cost or compliance barriers. The oral route is ibutamoren's single largest clinical advantage over injectable recombinant GH. Whether that advantage is sufficient to justify the 800-million-to-2-billion-dollar approval cost for a compound with no patent protection is a market question, not a science question.

A practical decision framework for clinicians advising patients who ask about ibutamoren:

1. Is the patient already on injectable GH or IGF-1 therapy? If yes, adding a GH secretagogue may amplify the glucose-elevating effect additively. Monitor HbA1c at 3 months.
2. Does the patient have pre-diabetes (fasting glucose 100 to 125 mg/dL) or a BMI above 30? The fasting-glucose signal at 25 mg is consistent enough to warrant starting at 10 mg with monthly glucose monitoring if ibutamoren is used.
3. Is the patient asking about ibutamoren for sleep quality or anti-aging? Cite the Copinschi data (20% increase in stage IV sleep) and note that this was a 16-subject study. Calibrate expectations accordingly.
4. Active malignancy or strong family history of IGF-1-driven cancer (breast, prostate, colorectal)? The Endocrine Society guideline caution about GH replacement in active malignancy applies. [11]